LONDON–(BUSINESS WIRE)–#Biotechnology–The global Duchenne muscular dystrophy (DMD) therapeutics market size is poised to reach USD 2.23 billion by 2023, according to a new report by Technavio, progressing at a CAGR of 37% during the forecast period.
Read the 132-page research report with TOC on “Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis Report by type (biologics and small molecules) and geographical regions (North America, Europe, Asia, and ROW) 2019 – 2023″ Request Free Sample Pages
The market is driven by the high unmet need. In addition, patient assistance programs are anticipated to further boost the Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period.
Despite recent approvals, the global DMD therapeutics market represents a high unmet need for affordable therapies that can reverse the progression of DMD. This creates significant opportunity for vendors to enter the global DMD therapeutics market to cater to the high unmet demand. Some major vendors like Santhera, Sarepta, Catabasis, and Roche are expected to enter the market during the forecast period with their novel molecules for the treatment of this indication. Moreover, the strong distribution network of these vendors, along with the presence of reimbursement policies, ensures increased patient adherence to these therapies. Thus, such factors are expected to boost market growth largely during the forecast period.
Furthermore, various governments have come up with patient assistance programs to help reduce the cost burden associated with these therapeutics. Vendors have also introduced patient assistance programs to help patients overcome the high costs associated with treatment. For instance, The Patient Co-Pay Assistance Program is an initiative started by Sarepta to provide financial benefits to patients with commercial health insurance. Thus, such programs are expected to help patients in overcoming the high costs associated with the treatment, which will increase adherence to the treatment and drive the growth of the Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period.
For More Information: Request Free Sample Pages
The report includes detailed profiles of the leading companies & prominent vendors of the market:
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
Market Segmentation by Category and Product Types:
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market can be broadly categorized into the following type:
- Biologics
- Small Molecules
Key Regions for the Duchenne Muscular Dystrophy (DMD) Therapeutics Market:
Featuring a breakdown of region wise market shares until 2019.
- North America
- Europe
- Asia
- ROW
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare Market are:
Polysomnography Devices Market – Global Polysomnography Devices Market by end-users (hospitals, sleep clinics and diagnostic laboratories, ASCs, and homecare) and geography (Asia, Europe, North America, and ROW).
Smart Pills Market – Global Smart Pills Market by application (diagnostics and drug therapy) and geography (Asia, Europe, North America, and ROW).
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com